38 related articles for article (PubMed ID: 2771996)
21. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
[TBL] [Abstract][Full Text] [Related]
22. Treatment of superficial bladder cancer.
Grossman HB
Compr Ther; 1995 May; 21(5):245-8. PubMed ID: 7621655
[No Abstract] [Full Text] [Related]
23. BCG therapy of superficial bladder tumors.
Herr HW
Prog Clin Biol Res; 1989; 303():369-74. PubMed ID: 2674999
[No Abstract] [Full Text] [Related]
24. [Immunotherapy in superficial bladder carcinoma].
Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
[TBL] [Abstract][Full Text] [Related]
25. [BCG vaccine and prevention of recurrence of superficial cancer of the bladder. Have all the possibilities been exhausted?].
Vera-Donoso CD; Llopis Minguez B; Gallego Gómez J; Jiménez Cruz JF
Actas Urol Esp; 1989; 13(4):233-5. PubMed ID: 2678933
[No Abstract] [Full Text] [Related]
26. Low-dose BCG-Pasteur strain in the treatment of superficial bladder cancer: preliminary results.
Pagano F; Bassi P; Milani C; Meneghini A; Tuccitto G; Garbeglio A; Guazzieri S
Prog Clin Biol Res; 1989; 310():253-61. PubMed ID: 2672015
[No Abstract] [Full Text] [Related]
27. BCG immunotherapy for superficial bladder cancer.
Lockyer CR; Gillatt DA
J R Soc Med; 2001 Mar; 94(3):119-23. PubMed ID: 11285791
[No Abstract] [Full Text] [Related]
28. [Carcinoma in situ of the urinary bladder--definition and status of treatment].
Otto T; Rübben H
Urologe A; 1991 May; 30(3):163-6. PubMed ID: 1871934
[TBL] [Abstract][Full Text] [Related]
29. The experience with intravesical BCG-immunotherapy in the management of superficial bladder cancer in the United Kingdom.
Robinson MR
Prog Clin Biol Res; 1989; 310():147-51. PubMed ID: 2672013
[No Abstract] [Full Text] [Related]
30. [Immunotherapy of urothelial neoplasms. Experimental and clinical implications of alpha interferon].
Carballido J; Alvarez-Mon M; Olivier C; Moltó L
Arch Esp Urol; 1990; 43 Suppl 2():149-58. PubMed ID: 2096776
[No Abstract] [Full Text] [Related]
31. Vesicorenal reflux and intravesical chemotherapy.
Mazeman E; Gilliot P
Prog Clin Biol Res; 1989; 303():517-22. PubMed ID: 2675008
[No Abstract] [Full Text] [Related]
32. The role of photodynamic therapy in the treatment of recurrent superficial bladder cancer.
Walther MM
Urol Clin North Am; 2000 Feb; 27(1):163-70. PubMed ID: 10696255
[TBL] [Abstract][Full Text] [Related]
33. [Changing profile of mycobacterial infection: current understanding].
Yamada T
Nihon Saikingaku Zasshi; 1994 Sep; 49(5-6):745-9. PubMed ID: 7830317
[No Abstract] [Full Text] [Related]
34. Pathologic and structural changes in the bladder after BCG intravesical therapy in men.
Pagano F; Bassi P; Milani C; Dalla Palma P; Rebuffi AG; Poletti A; Parenti A
Prog Clin Biol Res; 1989; 310():81-91. PubMed ID: 2771996
[No Abstract] [Full Text] [Related]
35. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
[No Abstract] [Full Text] [Related]
36. Percutaneous, oral, or intravesical BCG administration: what is the optimal route?
Lamm DL; Sarodosy MS; DeHaven JI
Prog Clin Biol Res; 1989; 310():301-10. PubMed ID: 2672018
[No Abstract] [Full Text] [Related]
37. [Treatment and follow-up of superficial bladder cancer].
Raitanen M
Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
[No Abstract] [Full Text] [Related]
38. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
